Results 161 to 170 of about 4,362,156 (310)

Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway. [PDF]

Immunol Rev, 2023
Dreismann AK, Hallam TM, Tam LC, Nguyen CV, Hughes JP, Ellis S, Harris CL.   +6 more
europepmc   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

A novel targeting modality for renal cell carcinoma: human osteocalcin promoter-mediated gene therapy synergistically induced by vitamin C and vitamin D

, 2012
[[abstract]]"Background Advanced renal cell carcinoma (RCC) frequently develops skeletal metastasis and is highly resistant to conventional therapies.
謝嘉玲;Hsieh, Chia-Ling
core  

Bioinformatics driven in gene targeting platform for gold anticancer strategy delivery. [PDF]

Mater Today Bio
Jiang C, Wen H, Chen J, Han N, Sun X, Zhang Y, Hu Y, Shu G, Yin G, Wang M.   +9 more
europepmc   +1 more source

Gene targeting techniques for Huntington's disease. [PDF]

Ageing Res Rev, 2021
Fields E, Vaughan E, Tripu D, Lim I, Shrout K, Conway J, Salib N, Lee Y, Dhamsania A, Jacobsen M, Woo A, Xue H, Cao K.   +12 more
europepmc   +1 more source

Targeted gene repair [PDF]

Gene Therapy, 1999
openaire   +2 more sources

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Inflation Targeting and Output Stabilisation [PDF]

Inflation targeting has been criticised for being ‘inflation only’ targeting and hence, for ignoring output and employment. This paper argues that this criticism is misplaced.
Guy Debelle
core  

Development of Modular Geminivirus-Based Vectors for High Cargo Expression and Gene Targeting in Plants. [PDF]

Plant Biotechnol J
Neubauer M, Vollen K, Zhao C, Ascencio-Ibáñez JT, Hanley-Bowdoin L, Stepanova AN, Alonso JM.   +6 more
europepmc   +1 more source

Combinatorial gene targeting in primary human hematopoietic stem and progenitor cells. [PDF]

Sci Rep, 2022
Bäckström A, Yudovich D, Žemaitis K, Nilsén Falck L, Subramaniam A, Larsson J.   +5 more
europepmc   +1 more source